Attapon Cheepsattayakorn1,3*, Ruangrong Cheepsattayakorn2 and Porntep Siriwanarangsun3
110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
3Faculty of Medicine, Western University, Pathumtani Province, Thailand
*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.
Received: September 04, 2021; Published: October 20, 2021
A recent study in the USA of a total of 35,691 pregnant participants 16 to 54 years of age from December 14, 2020, to February 28, 2021  was conducted by using data from the v-safe pregnancy registry , “v-safe after vaccination health checker” surveillance system , and the Vaccine Adverse Event Reporting System (VAERS, a national spontaneous-reporting (passive-surveillance) system established in 1990 and administered by the US CDC and the US FDA) , the three US vaccine safety monitoring systems for characterization the initial safety of mRNA COVID-19 vaccines in pregnant participants . Of 3,958 mRNA-vaccine (Pfizer/BioNTech vaccine, Moderna vaccine)-received-pregnant participants registered in the v-safe pregnancy registry, 115 (13.9%) of 827 completed pregnant participants had a pregnant loss and 712 (86.1%) had a live birth (mostly among third-trimester-COVID-19-vaccinated pregnant participants) . Preterm birth (9.4%) and small-size-gestational age (3.2%) were the adverse neonatal outcomes . The study revealed no neonatal death .
Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Vaccination in Pregnant Women”. Acta Scientific Microbiology 4.11 (2021): 46-48.
Copyright: © 2021 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.